Localised therapies using 3D-printed collagen-based micro-implant for ocular indications

Current limitations in treating retinal diseases like age-related macular degeneration (AMD) and diabetic retinopathy (DR) are due to the short ocular residence time of biologics and the difficulty of precise drug delivery. In turn, frequent injections are required, hindering patient compliance, and increasing healthcare costs. This study explores the development of a collagen-based implant using 3D bioprinting platform to address these challenges. The implant offers dual functionalities: i) sustained and localized drug delivery using in situ polymerization collagen (IPC) to act as reservoirs for prolonged release of biologics to the target tissue and ii) scaffold stability through the incorporation of methacrylated hyaluronic acid (HAMA) to enhance the mechanical properties of the IPC implant, making it suitable for 3D printing of targeted drug delivery systems. This data demonstrates that IPC-HAMA implants exhibit slow drug release and scaffold stability for over 80 days. Additionally, 3D bioprinting enables precise targeting and volumetric control within the simulated vitreous humor, overcoming challenges associated with traditional injection methods. This innovative approach has the potential to revolutionize drug delivery and localized tissue therapy for retinal diseases.